A RANDOMISED CONTROLLED TRIAL OF RIFAXIMIN TO PREVENT RELAPSE OF CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHOEA AFTER RESOLUTION WITH STANDARD THERAPY  

(1) University of Nottinghan,NIHR Nottingham Digestive Diseases Biomedical Research Centre,Nottingham,United Kingdom

(2) University of Nottingham,Nottingham Clinical Trials Unit,Nottingham,United Kingdom

(3) University of Warwick,Warwick Clinical Trials Unit,Coventry,United Kingdom

(4) Nottingham University Hospitals NHS Trust,Nottingham,United Kingdom



This item was part of UEG Week 2017

This item can be cited as: United European Gastroenterology Journal 2017; 5 (Supplement 1)

You may be interested in:

Should we treat uncomplicated diverticulitis as an immune disease?
English, Presentation, 2015, IBD, Immunology, Neurogastroenterology & Motility, Primary Care, Surgery, Young GI Track, Gut Microbiota
EC cells and potential role in intestinal disorders
English, Presentation, Surgery, 2019

Categorisation:

  • Format
    • Abstract
  • Year
    • 2017